During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

Context Prostate cancer is the most frequent male cancer. Since the median age of
diagnosis is 66 yr, many patients require both geriatric and urologic evaluation if treatment is …

Background: This study investigated prostate cancer (PC)-specific survival and overall
survival (OS) in a population-based castration-resistant PC (CRPC) cohort. Methods: Data …

Importance Many patients 65 years or older with metastatic castration-resistant prostate
cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered …

Introduction The importance of rational drug therapy is increasing with the aging of the
population. Since one of the main reasons for inappropriate drug prescribing is also the “age …

The management of prostate cancer in the elderly is a major public health concern in most
countries. Currently, most prostate cancers are diagnosed in elderly males. The elderly …

The incidence of prostate cancer among older men has increased in many countries,
including Asian countries. However, older patients are ineligible for inclusion in large …

Introduction Reductions in testosterone concentration play a significant role in the treatment
of prostate cancer. We studied the role of testosterone as a prognostic marker for advanced …

Abstract Background No North‐American study tested the survival benefit of chemotherapy
in de novo metastatic prostate cancer according to race/ethnicity. We addressed this void …

Introduction Older patients are often deemed ineligible for clinical research, and many
frequently-used endpoints and outcome measures are not as relevant for older patients for …